Login
$ZNTL
$1.63 +$0.03 (1.87%) After hours

$ZNTL SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

SAN DIEGO, November 9, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dr...

27 Oct 2026 SCHEDULE 13G/A
01 Oct 2026 Form 4: Bruns Ingmar, Chief Medical Officer

Received 9,727 shares as a grant or award ($21.2K)

19 Aug 2026 SCHEDULE 13G/A
19 Aug 2026 Form 4: Walters Group, 10% owner and 2 others

Bought 4,335,000 shares ($15.2M)

14 Aug 2026 8-K: Other Events

TD Securities (USA) LLCGuggenheim Securities, LLCOppenheimer & Co. Inc.

14 Aug 2026 424B5
13 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 424B5
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

SAN DIEGO — August 6, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dri...

30 Jul 2026 SCHEDULE 13G
18 Jun 2026 Form 4: Johnson David Michael, Director

Received 57,100 shares as a grant or award

18 Jun 2026 Form 4: Skvarka Jan, Director

Received 57,100 shares as a grant or award

18 Jun 2026 Form 4: Walker Luke Nathaniel, Director

Received 57,100 shares as a grant or award

18 Jun 2026 Form 4: Kariuki Enoch, Director

Received 57,100 shares as a grant or award

18 Jun 2026 Form 4: Myers Scott Dunseth, Director

Received 57,100 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support